# Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

> **NCT03123978** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Prostate Carcinoma
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** Niclosamide

## Key facts

- **NCT ID:** NCT03123978
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-09
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-04-19
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03123978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03123978, "Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03123978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*